Current geopolitical tensions and rapid technological developments have necessitated an urgent reassessment of biological risks and their...

Medical diagnostics, biomanufacturing, and many other parts of the bioeconomy rely on synthetic nucleic acids (NAs). Clinicians and...

Biotech: Ensure safety to maximise progress. Safeguards needed for responsible innovation.

With a return-on-investment of CHF 290 for every CHF 1 spent during an ordinary winter, savings orders of magnitudes higher during a...

Greetings! The last six months at Pour Demain have been dominated by political negotiations.

Switzerland can further increase safety in laboratories. Pour Demain has derived recommendations from more than 15 interviews with...

According to the white paper, Pour Demain recommends that Switzerland provides 50 million per year for international pandemic...

Study on Early Warning System Against Pandemics in Switzerland

The next pandemic is only a matter of time. To prevent and fight epidemics and pandemics, Switzerland needs versatile and complementary...

Public event in collaboration with Reatch, 9 June 2022, University of Zurich Covid-19 has shown that pandemics are a real threat. With...

Switzerland must strengthen the long-term pathogen surveillance in order to be ready for the next pandemic, writes Laurent Bächler,...